AU2023206363A1 - Vegf and tie2-binding fusion protein and uses thereof - Google Patents

Vegf and tie2-binding fusion protein and uses thereof Download PDF

Info

Publication number
AU2023206363A1
AU2023206363A1 AU2023206363A AU2023206363A AU2023206363A1 AU 2023206363 A1 AU2023206363 A1 AU 2023206363A1 AU 2023206363 A AU2023206363 A AU 2023206363A AU 2023206363 A AU2023206363 A AU 2023206363A AU 2023206363 A1 AU2023206363 A1 AU 2023206363A1
Authority
AU
Australia
Prior art keywords
fusion protein
identity
seq
vegf
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023206363A
Other languages
English (en)
Inventor
Minkyung CHOO
Philip DUROST
Sangyeul HAN
Kwangsoo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ingenia Therapeutics Inc
Original Assignee
Ingenia Therapeutics Inc
Ingenia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenia Therapeutics Inc, Ingenia Therapeutics Inc filed Critical Ingenia Therapeutics Inc
Publication of AU2023206363A1 publication Critical patent/AU2023206363A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023206363A 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof Pending AU2023206363A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US63/299,177 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US63/310,359 2022-02-15
US202263335805P 2022-04-28 2022-04-28
US63/335,805 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
AU2023206363A1 true AU2023206363A1 (en) 2024-08-15

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023206363A Pending AU2023206363A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Country Status (16)

Country Link
US (1) US20230287109A1 (https=)
EP (1) EP4463482A4 (https=)
JP (1) JP2025503704A (https=)
KR (1) KR20250005053A (https=)
AU (1) AU2023206363A1 (https=)
CA (1) CA3242904A1 (https=)
CL (2) CL2024002106A1 (https=)
CO (1) CO2024010934A2 (https=)
CR (1) CR20240342A (https=)
DO (1) DOP2024000136A (https=)
GE (1) GEAP202416581A (https=)
IL (1) IL314219A (https=)
JO (1) JOP20240158A1 (https=)
MX (1) MX2024008737A (https=)
PE (1) PE20260003A1 (https=)
WO (1) WO2023137395A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178471A1 (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 vegf에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359833B (es) * 2011-08-19 2018-10-12 Regeneron Pharma Anticuerpos anti-tie2 y usos de los mismos.
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
US10597453B2 (en) * 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
WO2020068653A1 (en) * 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
JP7638989B2 (ja) * 2019-11-21 2025-03-04 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use

Also Published As

Publication number Publication date
WO2023137395A1 (en) 2023-07-20
CL2025002473A1 (es) 2025-11-14
CL2024002106A1 (es) 2025-03-28
JOP20240158A1 (ar) 2024-07-14
PE20260003A1 (es) 2026-01-06
MX2024008737A (es) 2024-09-11
EP4463482A4 (en) 2026-05-06
CO2024010934A2 (es) 2024-10-31
CR20240342A (es) 2024-09-18
US20230287109A1 (en) 2023-09-14
EP4463482A1 (en) 2024-11-20
IL314219A (en) 2024-09-01
KR20250005053A (ko) 2025-01-09
CA3242904A1 (en) 2025-03-14
JP2025503704A (ja) 2025-02-04
GEAP202416581A (en) 2024-12-10
DOP2024000136A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
JP7314356B2 (ja) 改変ｊ鎖を有する結合分子
US20210040181A1 (en) Targeted therapeutics based on engineered proteins that bind egfr
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
US11498962B2 (en) Anti-angiopoietin-2 antibodies that induce Tie2 activation
KR102455680B1 (ko) 신규 항인간 Tie2 항체
EP3646887A1 (en) Conjugate of vegf-grab protein and drug, and use thereof
US20160024483A1 (en) Method of treating eye disease using glycosylated vegf decoy receptor fusion protein
JP7700189B2 (ja) 抗Ｔｉｅ２抗体およびその使用
EP4386009A1 (en) Bispecific fusion polypeptide and application thereof
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
JP2025508317A (ja) 抗ｃｄ３及び抗ｃｄ２０二重特異性抗体、並びにその使用
CN117529494A (zh) 包括il-12激动剂多肽的嵌合分子
US20230287109A1 (en) VEGF and TIE2-Binding Fusion Protein and Uses Thereof
CN114656567A (zh) 抗icos抗体及其应用
EP4559932A1 (en) Multispecific antibody and use thereof
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
HK40118737A (zh) 结合vegf和tie2的融合蛋白及其用途
KR20140025836A (ko) 항 ＨＥＲ2/Ｎｅｕ 단일클론항체와 ＩＬ-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
US12617848B2 (en) Methods of treating ocular pathologies using bifunctional molecules that target growth factors
WO2025070337A1 (ja) 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用
HK40130178A (en) Antibody binding to tie2 and use thereof
WO2025140497A1 (zh) Pvrig结合蛋白、双特异性抗体及其应用
CN119219777A (zh) 4-1bb结合蛋白